Vol 5, No 6 (December 29, 2016): Translational Lung Cancer Research (Emerging Treatment Options for Brain Metastases from Non-small Cell Lung Cancer)

Preface on “Emerging treatment options for brain metastases from non-small cell lung cancer”

Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future

Achievements and future developments of ALK-TKIs in the management of CNS metastases from ALK-positive NSCLC

Non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases: role of tyrosine kinase inhibitors (TKIs) and evidence in favor or against their use with concurrent cranial radiotherapy

State of the art of chemotherapy for the treatment of central nervous system metastases from non-small cell lung cancer

Anti-angiogenetic therapies for central nervous system metastases from non-small cell lung cancer

Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?—current evidence and future perspectives

Defining the endpoints: how to measure the efficacy of drugs that are active against central nervous system metastases

Pros: After stereotactic ablative radiotherapy for a peripheral early-stage non-small cell lung cancer, radiological suspicion of a local recurrence can be sufficient indication to proceed to salvage therapy

Cons: After lung stereotactic ablative radiotherapy for a peripheral stage I non-small cell lung carcinoma, radiological suspicion of a local recurrence is not sufficient indication to proceed to salvage therapy

Rebuttal from Dr. Nguyen and Dr. Palma

Rebuttal from Dr. Bezjak and Dr. Giuliani

ASCEND-2: a canary in a coal mine for descending to second-line treatment for ALK-rearranged non-small cell lung cancer

Comparison of methods for circulating cell-free DNA isolation using blood from cancer patients: impact on biomarker testing

Impact of dose calculation models on radiotherapy outcomes and quality adjusted life years for lung cancer treatment: do we need to measure radiotherapy outcomes to tune the radiobiological parameters of a normal tissue complication probability model?

Statistic and dosimetric criteria to assess the shift of the prescribed dose for lung radiotherapy plans when integrating point kernel models in medical physics: are we ready?

Statistical control process to compare and rank treatment plans in radiation oncology: impact of heterogeneity correction on treatment planning in lung cancer

Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance

A rare case of palatin tonsillar metastasis from small cell lung cancer

Unexpected long survival of brain oligometastatic non-small cell lung cancer (NSCLC) treated with multimodal treatment: a single-center experience and review of the literature

Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature

Metastatic lung cancer in the age of targeted therapy: improving long-term survival